Sierra Leone
Tuberculosis profile
| High HIV burden |
Population  2013 6.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (0.87–5) 43 (14–82)
Mortality (HIV+TB only) 0.61 (0.3–1) 10 (4.9–17)
Prevalence  (includes HIV+TB) 26 (13–44) 432 (216–721)
Incidence  (includes HIV+TB) 19 (15–24) 313 (240–398)
Incidence (HIV+TB only) 2.2 (1.7–2.8) 36 (27–46)
Case detection, all forms (%) 63 (50–83)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.9 (0–4.7) 23 (5–54)
MDR-TB cases among notified pulmonary
TB cases
100 (0–530) 110 (25–270)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7 390   235
Pulmonary, clinically diagnosed 3 958    
Extrapulmonary 489    
       
Total new and relapse 12 072    
Previously treated, excluding relapses 262    
Total cases notified 12 334    
Among 7 390 new and relapse cases:
103 (1%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 11 190 (91)
HIV-positive TB patients 1 417 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 719 (51)
HIV-positive TB patients on antiretroviral therapy (ART) 901 (64)
HIV-positive people screened for TB 9 048  
HIV-positive people provided with IPT 668  
Treatment success rate (%)
New cases registered in 2012 90
Previously treated cases registered in 2012 81
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-03 Data: www.who.int/tb/data